[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441049":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":37,"responsibleParty":54,"collaborators":57,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":20,"enrollmentInfo":81,"targetDuration":20,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":20,"overallStatus":40,"whyStopped":20,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Sunnybrook Health Sciences Centre","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SBRT for Medically Inoperable RCC","EXPERIMENTAL","35-45 Gy in five fractions (7-9 Gy\u002Fday)",[13],"Radiation: Stereotactic body radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Stereotactic body radiotherapy","SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"William Chu, MD, FRCPC","Sunnybrook Health Sciences Center","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Chris Zehr","CONTACT","416-480-6100","88144","chris.zehr@sunnybrook.ca",{"name":34,"role":29,"phone":30,"phoneExt":35,"email":36},"Kerri Durrant","89518","keri.durrant@sunnybrook.ca",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":20,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Sunnybrook Health Sciences","RECRUITING","Toronto","Ontario","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-79.39864,43.70643,{"lat":49,"lon":48},[52],{"name":53,"role":29,"phone":20,"phoneExt":20,"email":20},"William Chu",{"type":25,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"William Chu, MD, MSc, FRCPC","Assistant Professor, Department of Radiation Oncology, University of Toronto",[58,60,62,64,66,68],{"name":59,"class":6},"Juravinski Cancer Center",{"name":61,"class":6},"Health Sciences North",{"name":63,"class":6},"Grand River Regional Cancer Centre",{"name":65,"class":6},"British Columbia Cancer Agency",{"name":67,"class":6},"London Health Sciences Centre",{"name":69,"class":70},"Durham Regional Cancer Centre","UNKNOWN","100441049","assessment-of-quality-of-life-and-outcomes-in-patients-with-primary-renal-cell-carcinoma-treated-with-sbrt-100441049",false,"NCT05023265","Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT","Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II Study","AQuOS-II","Inclusion Criteria:\n\n* Patients ≥18 years old\n* Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)\n* Primary lesion \\>3 cm, or recurrent lesion following local ablative therapy\n* Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting\n* ECOG 0-2\n* Written informed consent\n* Participants must be able to understand the English-language or with the aid of a translator\n\nExclusion Criteria:\n\n* Primary Lesion \\>20cm\n* Evidence of distant metastatic disease\n* Previous abdominal RT in vicinity of kidney preventing definitive SBRT\n* History of major radiosensitivity syndrome\n* Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer)\n* Currently pregnant or lactating","ALL","18 Years",{"count":82,"type":83},70,"ESTIMATED","INTERVENTIONAL",[86],"NA","This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).",[89],"Renal Cell Carcinoma","2026-04-27",{"date":92,"type":93},"2026-04-28","ACTUAL",{"date":95,"type":93},"2022-02-08",{"date":97,"type":83},"2026-10-01",{"name":5,"class":6},1]